(a) Binding of in vitro translated 35S-labeled HA-HIRA(421–729) and the indicated B-domain deletion mutants to 35S-labeled Myc-ASF1a.
(b) Binding of in vitro translated 35S-labeled GFP-HIRA(421–729) and the indicated C-terminal deletion mutants to 35S-labeled Myc-ASF1a.
(c) Binding of in vitro translated 35S-labeled HA-HIRA(421–729) to 35S-labeled Myc-ASF1a in the presence of 0, 1, 10 and 50µg of the wild-type HIRA peptide, RTADGRRRITPLCIA, or 50µg of the scrambled peptide, GRAARITPRDTLRCI. The height of the square and triangle indicates relative peptide concentrations.